|
Hot Stocks
|
SpringWorks Therapeutics… ShowHide Related Items >><< SWTX SpringsWorks Therapeutics - 05/24/22
- SpringsWorks Therapeutics: Nirogacestat achieved endpoints in Phase 3 DeFi trial
- 04/19/22
- SpringsWorks announces agreeement with Regeneron for nirogacestat
- 12/10/21
- SpringsWorks Therapeutics announces trial collaboration with AbbVie
- 12/06/21
- SpringsWorks Therapeutics doses first patient in Phase 1b/2 nirogacestat study
- 04/29/22
- SK bioscience, GSK report COVID-19 vaccine candidate meets Phase 3 objectives
- 04/27/22
- GSK expects COVID-19 solutions to contribute similar sales level to 2021
- 04/27/22
- GlaxoSmithKline sees FY Specialty Medicines sales up 10% at CER
- 04/27/22
- GlaxoSmithKline CEO says delivered 'strong' Q1 results
SWTX SpringsWorks Therapeutics - 05/24/22 Goldman Sachs
- SpringsWorks Therapeutics price target raised to $82 from $76 at Goldman Sachs
- 03/01/22 H.C. Wainwright
- SpringsWorks Therapeutics price target raised to $142 from $137 at H.C. Wainwright
- 10/27/21 Wedbush
- Wedbush recommends buying SpringsWorks shares ahead of BLENREP combo data
- 09/08/21 JPMorgan
- SpringsWorks price target raised to $105 from $97 at JPMorgan
- 05/19/22 Deutsche Bank
- GlaxoSmithKline price target raised to 1,750 GBp at Deutsche Bank
- 05/17/22 Roth Capital
- Ideaya Biosciences price target raised to $46 from $42 at Roth Capital
- 05/13/22 Jefferies
- Roche downgraded to Hold from Buy at Jefferies
- 04/29/22 Barclays
- GlaxoSmithKline price target raised to 1,800 GBp from 1,775 GBp at Barclays
SWTX SpringsWorks Therapeutics - 05/05/22
- SpringsWorks Therapeutics reports Q1 EPS ($1.26), consensus ($1.02)
- 02/24/22
- SpringsWorks Therapeutics reports Q4 EPS ($1.15), consensus (88c)
- 04/27/22
- GlaxoSmithKline reaffirms FY22 sales growth between 5%-7% at CER
- 04/27/22
- GlaxoSmithKline reports Q1 adjusted EPS 32.8p vs. 22.9p last year
- 04/13/22
- GlaxoSmithKline backs FY22 revenue view up 5%-7% at CER, consensus $47.34B
- 02/25/22
- Vir Biotechnology falls 5% after Q4 sales top estimates
- 05/25/22
- Nestle mulled GSK consumer deal, but dropped idea, Bloomberg reports
- 05/25/22
- Nestle considered GSK consumer deal, but dropped idea, Bloomberg says
- 03/30/22
- DOJ probes network accused of selling counterfeit HIV drugs, WSJ reports
- 02/06/22
- Two big Unilever investors want split or new chair, FT reports
SWTX SpringsWorks Therapeutics - 18:31 Today
- Fly Intel: After-Hours Movers
- 05/24/22
- What You Missed On Wall Street On Tuesday
- 05/24/22
- What You Missed On Wall Street This Morning
- 05/13/22
- Proven algorithm says sell these stocks now
- 04/13/22
- What You Missed On Wall Street On Wednesday
- 04/13/22
- What You Missed On Wall Street This Morning
- 04/13/22
- Fly Intel: Pre-market Movers
- 01/31/22
- Meet Lyell: Fly exclusive interview with CEO Liz Homans
- 05/09/22
- GlaxoSmithKline call volume above normal and directionally bullish
- 03/07/22
- GlaxoSmithKline put volume heavy and directionally bearish
- 01/21/22
- GlaxoSmithKline call volume above normal and directionally bullish
- 12/15/21
- GlaxoSmithKline call volume above normal and directionally bullish
|
|
On The Fly
| ShowHide Related Items >><< - 16:35 Today
- Red Robin jumps 13% to $9.76 after Q1 earnings beat
- 16:15 Today
- Red Robin backs FY22 adjusted EBITDA view of $90M-$90M
- 03/10/22
- Red Robin sees FY22 adjusted EBITDA $80M-$90M
- $378.10 /
+25.03 (+7.09%) - 16:33 Today
- Ulta Beauty jumps 7.6% to $406.50 after Q1 earnings beat and guidance raise
- 16:33 Today
- Ulta Beauty jumps 7.6% to $406.50 after Q1 earnings beat and guidance raise
- 05/19/22
- Ulta Beauty launches retail media network UB Media
- 03/28/22
- PayPal broadens access to post purchase services for merchants
- 16:30 Today
- Dell Technologies jumps 7% to $47.02 after Q1 results beat estimates
- 16:28 Today
- Dell Technologies ended Q1 with performance obligations of $42B
- 16:27 Today
- Dell Technologies co-COO calls Q1 a 'record first quarter'
- 05/23/22
- T-Mobile, Dell Technologies partner for 5G connectivity, edge compute
- 05/09/22
- Marvell to acquire Tanzanite in an all-cash transaction
- 04/20/22
- Marvell appoints Sara Andrews to board of directors
- 04/14/22
- Worldwide semiconductor revenue grew 26% in 2021, Gartner says
- 03/14/22
- Marvell CEO: The company is performing extremely well
- 03/24/22
- Autodesk to acquire The Wild, terms not disclosed
- 01/19/22
- Autodesk acquires Moxion cloud solution
- 01/06/22
- Autodesk names Rebecca Pearce Chief People Officer
- 12/16/21
- Autodesk to acquire ProEst, terms not disclosed
- 18:10 Today
- Adicet Bio's ADI-001 shows 67% response rate for NHL in Phase 1 trial
- 04/19/22
- Adicet Bio gets FDA fast track designation for lead candidate ADI-001
- 12/06/21
- Adicet Bio trading resumes
- 12/06/21
- Adicet Bio trading halted, volatility trading pause
- 17:34 Today
- PMV Pharmaceuticals: Lead program, PC14586 accepted as oral presentation at ASCO
- 04/27/22
- PMV Pharmaceuticals to present initial PC14586 Phase 1 data at ASCO
- 17:42 Today
- Zymeworks to present zanidatamab antibody data at ASCO
- 05/20/22
- Zymeworks rejects unsolicited acquisition proposal from All Blue Falcons FZE
- 05/04/22
- Zymeworks expects cash to fund operations into second half of 2023
- 04/29/22
- Zymeworks rises 31.7%
- 05/18/22
- PDS Biotechnology appoints Sanjay Zaveri to SVP, business development
- 04/19/22
- PDS Biotechnology receives $1.2M after selling NOL tax benefits
- 04/08/22
- PDS Biotechnology reports inducement grants under Nasdaq listing rule
- 03/31/22
- PDS Biotechnology expects cash to fund operations through end of 2023
- 16:23 Today
- Gap falls 14% to $9.60 after Q1 earnings miss and guidance cut
- 16:17 Today
- Gap reports Q1 SSS down 14% y/y
- 04/22/22
- Gap falls -17.9%
- 04/22/22
- Gap falls -22.2%
- 16:24 Today
- American Eagle down 4% to $13.50 after lowering outlook for year
- 16:19 Today
- American Eagle CEO says committed to 'right-setting the business'
- 03/02/22
- American Eagle says 'taking a cautious view of 2022'
- 12/29/21
- American Eagle completes acquisition of Quiet Logistics
- 16:17 Today
- Workday drops 7% to $155.50 after Q1 EPS misses estimates
- 05/16/22
- Lone Pine adds TSMC in Q1, exits KE Holdings and Adobe
- 02/28/22
- Workday sees FY23 subscription revenue at $5.53B-$5.55B, up 22% y/y
- 02/14/22
- Lone Pine takes stakes in Mastercard, Visa, exits Twitter, Meta Platforms
- $465.33 /
+25.32 (+5.75%) - 05/04/22
- Costco reports April sales of $17.33B, up 13.9%
- 04/13/22
- Costco increases quarterly cash dividend to 90c per share
- 04/06/22
- Costco reports March sales of $21.61B, up 18.7%
- 03/08/22
- Jones Soda's Fountain Syrup now sold at Costco Business Centers
IOVA Iovance Biotherapeutics - 16:13 Today
- Iovance announces clinical data for lifileucel in advanced melanoma
- 04/05/22
- Iovance Biotherapeutics provides regulatory update on lifileucel
- 03/15/22
- Iovance Biotherapeutics announces FDA allows IOV-4001 IND to proceed
- 01/10/22
- Iovance appoints Raj Puri as EVP, regulatory strategy, translational medicine
SWTX SpringsWorks Therapeutics - 05/24/22
- SpringsWorks Therapeutics: Nirogacestat achieved endpoints in Phase 3 DeFi trial
- 04/19/22
- SpringsWorks announces agreeement with Regeneron for nirogacestat
- 12/10/21
- SpringsWorks Therapeutics announces trial collaboration with AbbVie
- 12/06/21
- SpringsWorks Therapeutics doses first patient in Phase 1b/2 nirogacestat study
- 17:08 Today
- Mirati Therapeutics says disease control rate was 80% in study
- 05/19/22
- Mirati Therapeutics submits adagrasib MAA to EMA
- 05/16/22
- Mirati Therapeutics appoints Laurie Stelzer as CFO
- 03/21/22
- AnaptysBio names Daniel Faga as interim CEO, succeeding Hamza Suria
- 04/18/22 Raymond James
- Red Robin downgraded to Market Perform from Outperform at Raymond James
- 04/18/22 Raymond James
- Red Robin downgraded to Market Perform from Outperform at Raymond James
- 11/23/21 Benchmark
- Red Robin initiated with a Buy at Benchmark
- 11/11/21 Raymond James
- Red Robin price target lowered to $30 from $40 at Raymond James
- $378.10 /
+25.03 (+7.09%) - 05/25/22 Deutsche Bank
- Ulta Beauty price target lowered to $466 from $522 at Deutsche Bank
- 04/19/22 Piper Sandler
- Ulta Beauty price target lowered to $465 from $475 at Piper Sandler
- 04/06/22 Piper Sandler
- Piper lists winners and losers from semi-annual teen survey
- 03/16/22 Oppenheimer
- Estee Lauder price target lowered to $300 from $350 at Oppenheimer
- 05/25/22 Evercore ISI
- Dell Technologies added to 'Tactical Outperform' list at Evercore ISI
- 05/25/22 JPMorgan
- Dell Technologies price target lowered to $60 from $68 at JPMorgan
- 05/23/22 Citi
- Dell Technologies price target lowered to $65 from $70 at Citi
- 04/19/22 KGI Securities
- Dell Technologies initiated with a Neutral at KGI Securities
- 05/25/22 Susquehanna
- Marvell price target lowered to $90 from $105 at Susquehanna
- 05/23/22 B. Riley
- Marvell price target lowered to $72 from $95 at B. Riley
- 05/23/22 UBS
- Marvell price target lowered to $80 from $95 at UBS
- 05/20/22 Oppenheimer
- Marvell price target lowered to $90 from $110 at Oppenheimer
- 05/23/22 Stifel
- Autodesk price target lowered to $230 from $285 at Stifel
- 05/23/22 RBC Capital
- Autodesk price target lowered to $255 from $295 at RBC Capital
- 05/23/22 Deutsche Bank
- Deutsche Bank downgrades Autodesk on risk to consensus estimates
- 05/23/22 Deutsche Bank
- Autodesk downgraded to Hold from Buy at Deutsche Bank
- 03/30/22 SMBC Nikko
- Adicet Bio initiated with an Outperform at SMBC Nikko
- 03/17/22 JMP Securities
- Adicet Bio price target lowered to $21 from $30 at JMP Securities
- 03/08/22 Truist
- Adicet Bio initiated with a Buy at Truist
- 03/04/22 Jefferies
- Adicet Bio initiated with a Buy at Jefferies
- 03/02/22 Oppenheimer
- Oppenheimer upgrades PMV Pharmaceuticals to Outperform with $30 price target
- 03/02/22 Oppenheimer
- PMV Pharmaceuticals upgraded to Outperform from Perform at Oppenheimer
- 09/22/21 Goldman Sachs
- PMV Pharmaceuticals upgraded to Buy from Neutral at Goldman Sachs
- 08/19/21 Oppenheimer
- PMV Pharmaceuticals initiated with a Perform at Oppenheimer
- 05/23/22 H.C. Wainwright
- Zymeworks price target lowered to $40 from $44 at H.C. Wainwright
- 05/09/22 Citi
- Zymeworks should reject 'opportunistic' $10.50 per share offer, says Citi
- 05/05/22 Guggenheim
- Zymeworks upgraded to Buy at Guggenheim amid low expectations
- 05/05/22 Guggenheim
- Zymeworks upgraded to Buy from Neutral at Guggenheim
- 05/13/22 Alliance Global Partners
- PDS Biotechnology price target lowered to $16 from $18 at Alliance Global Partners
- 10/21/21 H.C. Wainwright
- H.C. Wainwright says PDS Biotechnology temporary hold shouldn't spark concerns
- 08/12/21 H.C. Wainwright
- PDS Biotechnology price target lowered to $15 from $20 at H.C. Wainwright
- 06/28/21 Cantor Fitzgerald
- PDS Biotechnology initiated with an Overweight at Cantor Fitzgerald
- 05/23/22 Citi
- Gap downgraded to Sell from Neutral at Citi
- 05/17/22 UBS
- Gap price target lowered to $14 from $18 at UBS
- 05/16/22 JPMorgan
- Gap price target lowered to $11 from $14 at JPMorgan
- 04/25/22 Guggenheim
- Guggenheim upgrades Gap to Buy with shares 70% off highs
- 05/23/22 Citi
- American Eagle downgraded to Neutral from Buy at Citi
- 05/17/22 B. Riley
- American Eagle price target lowered to $32 from $41 at B. Riley
- 05/16/22 JPMorgan
- American Eagle price target lowered to $20 from $29 at JPMorgan
- 04/11/22 JPMorgan
- American Eagle price target lowered to $29 from $32 at JPMorgan
- 05/23/22 Cowen
- Workday price target lowered to $250 from $310 at Cowen
- 05/20/22 DA Davidson
- Workday price target lowered to $250 from $300 at DA Davidson
- 05/20/22 Barclays
- Workday price target lowered to $238 from $319 at Barclays
- 05/18/22 Wells Fargo
- Workday price target lowered to $300 from $340 at Wells Fargo
- $465.33 /
+25.32 (+5.75%) - 05/25/22 Deutsche Bank
- Costco price target lowered to $525 from $530 at Deutsche Bank
- 05/20/22 Oppenheimer
- Costco price target lowered to $500 from $645 at Oppenheimer
- 05/19/22 Truist
- Costco price target lowered to $503 from $634 at Truist
- 05/19/22 Stifel
- Costco price target lowered to $515 from $565 at Stifel
IOVA Iovance Biotherapeutics - 04/07/22 Truist
- Iovance Biotherapeutics price target lowered to $29 from $32 at Truist
- 04/07/22 Baird
- Iovance Biotherapeutics price target raised to $34 from $30
- 04/06/22 Oppenheimer
- Iovance 'good news' offset by timeline delay, says Oppenheimer
- 04/06/22 Goldman Sachs
- Iovance commentary supports potency assay progress, says Goldman Sachs
SWTX SpringsWorks Therapeutics - 05/24/22 Goldman Sachs
- SpringsWorks Therapeutics price target raised to $82 from $76 at Goldman Sachs
- 03/01/22 H.C. Wainwright
- SpringsWorks Therapeutics price target raised to $142 from $137 at H.C. Wainwright
- 10/27/21 Wedbush
- Wedbush recommends buying SpringsWorks shares ahead of BLENREP combo data
- 09/08/21 JPMorgan
- SpringsWorks price target raised to $105 from $97 at JPMorgan
- 05/20/22 Guggenheim
- Guggenheim upgrades Mirati to Buy on adagrasib's 'highly competitive profile'
- 05/20/22 Guggenheim
- Mirati Therapeutics upgraded to Buy from Neutral at Guggenheim
- 05/05/22 Stifel
- ASCO sets up as 'downside-biased' for Mirati investors, says Stifel
- 05/05/22 Citi
- Mirati Therapeutics price target lowered to $208 from $227 at Citi
- 16:14 Today
- Red Robin reports Q1 EPS (12c), consensus (73c)
- 03/10/22
- Red Robin reports Q4 EPS ($1.36), consensus (53c)
- $378.10 /
+25.03 (+7.09%) - 16:07 Today
- Ulta Beauty raises FY22 EPS view to $19.20-$20.10 from $18.20-$18.70
- 16:06 Today
- Ulta Beauty reports Q1 EPS $6.30, consensus $4.46
- 13:20 Today
- Notable companies reporting after market close
- 03/10/22
- Ulta Beauty sees FY2 EPS $18.20-$18.70, consensus $17.84
- 16:25 Today
- Dell Technologies reports Q1 adjusted EPS $1.84, consensus $1.39
- 13:20 Today
- Notable companies reporting after market close
- 02/24/22
- Dell Technologies reports Q4 adjusted EPS $1.72, consensus $1.95
- 02/24/22
- Notable companies reporting after market close
- 16:06 Today
- Marvell sees Q2 adjusted EPS 56c, +/- 3c per share, consensus 55c
- 16:05 Today
- Marvell reports Q1 adjusted EPS 52c, consensus 51c
- 13:20 Today
- Notable companies reporting after market close
- 03/03/22
- Marvell sees Q1 adjusted EPS 51c +/- 3c, consensus 50c
- 16:05 Today
- Autodesk sees FY23 non-GAAP EPS $6.43-$6.66, consensus $6.69
- 16:04 Today
- Autodesk sees Q2 non-GAAP EPS $1.54 - $1.60, consensus $1.60
- 16:03 Today
- Autodesk reports Q1 non-GAAP EPS $1.43, consensus $1.34
- 13:20 Today
- Notable companies reporting after market close
- 05/12/22
- Adicet Bio reports Q1 EPS (12c), consensus (18c)
- 03/15/22
- Adicet Bio reports Q4 EPS (47c), consensus (42c)
- 05/10/22
- PMV Pharmaceuticals reports Q1 EPS (41c), consensus (40c)
- 03/01/22
- PMV Pharmaceuticals reports 2021 EPS ($1.28), consensus ($1.22)
- 05/04/22
- Zymeworks reports Q1 adjusted EPS ($1.17), consensus ($1.67)
- 02/24/22
- Zymeworks reports Q4 EPS (95c), consensus ($1.14)
- 05/11/22
- PDS Biotechnology reports Q1 EPS (32c), consensus (22c)
- 03/31/22
- PDS Biotechnology reports 2021 EPS (66c), consensus (71c)
- 16:23 Today
- Gap cuts FY22 revenue view to down low-mid single digits from low single digits
- 16:19 Today
- Gap cuts FY22 EPS view to 30c-60c from $1.85-$2.05
- 16:17 Today
- Gap reports Q1 EPS (44c), consensus (13c)
- 13:20 Today
- Notable companies reporting after market close
- 16:18 Today
- American Eagle sees Q2 top-line growth to trend similarly to Q1
- 16:17 Today
- American Eagle reports Q1 EPS 16c, consensus 25c
- 03/02/22
- American Eagle reports Q4 adjusted EPS 35c, consensus 35c
- 03/02/22
- Notable companies reporting after market close
- 16:04 Today
- Workday sees Q2 subscription revenue $1.353B-$1.355B
- 16:02 Today
- Workday raises FY23 subscription revenue view to $5.537B-$5.557B
- 16:01 Today
- Workday reports Q1 EPS 83c, consensus 86c
- 13:20 Today
- Notable companies reporting after market close
- $465.33 /
+25.32 (+5.75%) - 16:20 Today
- Costco reports Q3 EPS $3.04, consensus $3.03
- 13:20 Today
- Notable companies reporting after market close
- 03/03/22
- Costco reports Q2 EPS $2.92, consensus $2.74
- 03/03/22
- Notable companies reporting after market close
IOVA Iovance Biotherapeutics - 05/05/22
- Iovance Biotherapeutics reports Q1 EPS (58c), consensus (64c)
SWTX SpringsWorks Therapeutics - 05/05/22
- SpringsWorks Therapeutics reports Q1 EPS ($1.26), consensus ($1.02)
- 02/24/22
- SpringsWorks Therapeutics reports Q4 EPS ($1.15), consensus (88c)
- 02/28/22
- Mirati Therapeutics reports Q4 EPS ($3.72), consensus ($3.00)
- 02/28/22
- Mirati Therapeutics reports Q4 EPS ($3072), consensus ($3.00)
|
